The Telegraph previously reported that Biomet would begin informal talks about a potential merger with Smith & Nephew. Sky News also reported earlier in the week that Smith & Nephew had rejected an $11 billion takeover from Johnson & Johnson in December. Stock prices jumped and then retreated after this announcement was made.
Smith & Nephew has an enterprise value of $10.3 billion. The company issued a statement today clarifying that it is not engaging in any discussions which could lead to a merger or takeover.
Read the Smith & Nephew release on the denial of mergers or acquisitions.
Read the report from The New York Times about Smith & Nephew.
Read other coverage on Smith & Nephew:
– Smith & Nephew Shares Jump After Rejecting Johnson & Johnson Acquisition
– Smith & Nephew Responds to FDA Letter of Warning
– Smith & Nephew Adds 100 Employees
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
